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Pharmacists are tasked with making decisions regarding the validity of prescriptions.  
Some have proposed factors that should be considered when evaluating a prescription’s validity.  
Yet, there is little known about the decision process that pharmacists employ at the time of 
dispensing and what information pharmacists deem relevant in that decision-making process.  
Using an online survey instrument, a sample of community pharmacists were divided into three 
groups and presented with a prescription scenario.  They were asked to rate the relevance of 
information, which is proposed to be appropriate and inappropriate, available at the time of 
dispensing. They were asked to consider this information in the context of deciding the validity 
of a prescription.  The medications presented in the groups were a schedule-III opioid pain 
medication, a non-controlled legend antibiotic, or a muscle relaxant with a potential for abuse. A 
total of 2,328 pharmacists were sent requests to participate.  This resulted in 104 usable 
responses, which represents a response rate of 7.7%.   The relevance of the information was 
shown to differ based on the prescription type.  Pharmacists attributed greater relevance to 
irrelevant factors when deciding the validity of prescription for a controlled substance than they 
did when evaluating an antibiotic (p<0.001).  This also was the case for suspicious factors 
(p<0.001) and determinative factors (p<0.003).  Other factors were explored also.  It seems clear 
that pharmacists are likely to judge different pieces of information about the patient and situation 
to be relevant depending on the medication being filled.  Further research is needed to 
understand the role that this plays in pharmacists’ decisions to fill and willingness to fill different 
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     A prescription is an order for medication for a patient issued by a medical practitioner 
(Scott, 2005).  A patient obtains prescribed medication by getting the prescription filled at a 
pharmacy.  The filling process includes a technician or pharmacist transcribing information into 
an electronic record of the prescription, printing labels and other information, supplying the 
medication from stock bottles, measuring or counting the medication, and bottling, labeling and 
selling the medication to the patient.  Thus, a medical practitioner’s prescription order has been 
transformed into medication for the patient at the pharmacy.   
       There are times when a prescription must be questioned for its validity, as not all 
prescriptions presented at the pharmacy are valid for processing.  The validity of a prescription 
could be suspect for many different reasons.  These reasons can range from relatively simple 
issues such as illegible handwriting of the prescribing physician or a clerical omission of 
required information on a prescription, to more difficult problems such as a physician prescribing 
a medication out of their scope of practice or prescribing a clinically inappropriate dose for a 
particular medication.  Or, the problem can be more disconcerting, such as an attempt of forgery 
by a patient attempting to illegally obtain a controlled substance.  It is the pharmacist that is 
tasked with recognizing potential problem prescriptions as it relates to the validity of the 
prescription. 
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       Prescriptions with illegible or missing information are usually easily recognized as 
needing intervention.  Prescriptions that are written outside of the scope of practice for a 
particular practitioner or clinically inappropriate dosing are also problems that can be recognized 
without much difficulty.  Forged prescriptions, however, are designed to misrepresent the truth 
and can be understandably more difficult to detect. 
        A forged prescription is a fake prescription and not valid under any circumstance.  A 
forgery may not be as easy to ascertain because the fake prescription’s purpose for existence is to 
mimic a valid prescription and to scam a pharmacy into dispensing a medication illegally.  A 
good forgery may be difficult to detect but a pharmacist is still tasked with recognizing and 
making the determination of prescription validity.  In the process of determining the validity of a 
prescription, a pharmacist has a wealth of available information.  At the time of filling a 
pharmacist often has available: patient demographics, patient insurance status, and physician 
information.  The pharmacist also may have, through electronic record, a history of a patient’s 
previous medications; and the pharmacist has the prescription itself.  It may have preprinted or 
computer-generated information about the physician and will also contain written or computer-
generated information about the patient, the medication, quantity, directions for use, and 
sometimes the diagnosis of the condition being treated. 
      A pharmacist must be aware of the laws and practice standards that regulate prescription 
validity and his or her corresponding responsibility to dispense medications in accordance with 
those laws.  There are guides and other resources available to pharmacists to help the process of 
determining the validity of a prescription.  Many state boards of pharmacy publish newsletters 
and the Drug Enforcement Agency publishes a Pharmacist’s Manual to help pharmacists 
evaluate potential forged prescriptions.  There are also pharmacy journals, widely available to 
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pharmacists, in which articles are published to help pharmacists interpret legal issues, including 
those involving prescription validity. 
      So, a pharmacist must make the determination of validity by deciding, based on available 
information, whether or not a prescription is valid for dispensing. A pharmacist has resources of 
law, practice standards, published guides, and professional experience to aid in determining 
validity.  It is the questioning of a prescription’s validity that moves it from the normal course of 
processing to another course of action. 
       It is reasonable to imagine the forged prescription might involve a controlled substance 
pain medication, specifically an opioid.  During the normal course of community pharmacy 
practice, the decision of prescription validity may involve a prescription for an opioid pain 
medication.  Opioids are some of the most widely and commonly prescribed medications in the 
United States (Rosenblum et al., 2008; Pletcher et al., 2008; Clark, 2002).  They are effective 
medications in pain therapy, but also have possible abuse potential (McCabe et al., 2006; 
Simoni-Wastila & Tompkins, 2001), and are considered a common choice for forgery attempts 
(Gilson et al., 2004; Drug Enforcement Agency [DEA], 2004). 
      Determining the validity of opioid prescriptions may lead to several possible outcomes.  
One potential outcome could result in a valid prescription going through a decision process, 
being accepted, and processed for dispensing.  As a second outcome, an invalid prescription may 
raise a “red flag” in the decision process and not get dispensed.    These first two outcomes are 
optimal.  Valid prescriptions proceed to dispensing, while forged or clinically suspect 
prescriptions get a different action. 
      The third outcome is a false negative.  An invalid prescription may go through a decision 
process and be processed for dispensing. This may result in forged or clinically inappropriate 
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prescriptions getting dispensed.  The consequence of this outcome is less than optimal; 
dispensing a forged opioid prescription results in a controlled prescription medication being used 
outside accepted legal parameters.  Opioid medications garnered from forged prescriptions may 
ultimately be used as street drugs (Gilson et al., 2004).  In another vein, a clinically inappropriate 
opioid prescription getting filled may have detrimental health consequences for the patient.         
      False positives, which is the fourth outcome, may also have negative implications for 
patient care. This occurs when a pharmacist deems a valid prescription to be a forgery when it is 
not and prevents a patient from receiving a needed medication. If a prescription for a prescribed 
opioid pain medication is deemed suspect, the patient may be left without pain relief, despite a 
legitimate prescription.    
       Given the implications of these latter two negative outcomes, it is worthwhile to further 
examine the pharmacist’s decision process for determining the validity of an opioid pain 
medication prescription and to explore what information pharmacists use in a prescription 
decision process.  Thus, the purpose of this study is to determine what information pharmacists 
consider relevant in determining whether a prescription is valid or not and whether the 






The dispensing process starts with a new prescription, then a technician or pharmacist 
transcribes that information into an electronic record of the prescription, labels and information 
are printed, stock bottles are used to supply the medication, medication is measured or counted, 
bottled, labeled for and sold to the patient, the end consumer in the process (Scott, 2005). The 
prescription is the order for medication for a patient issued by a medical practitioner (Scott, 
2005).  A prescription may be issued by an individual practitioner who is authorized by 
governing entities to prescribe medication for patients for a legitimate medical purpose within 
the prescriber’s scope of practice (Fink et al., 2006).   
 




To fill a prescription, a pharmacist must first gather patient information.  The information 
may be necessary for both legal and business reasons.  State and federal laws require certain 
patients’ information be provided prior to or at the time of dispensing of the prescription (Scott, 
2005).  Also, a third party payer may require specific patient-level information for proper 
processing and payment.  Commonly gathered information includes a patient’s name, address, 
phone number, date of birth, and insurance status.   
A prescription for a controlled substance has additional requirements for the patient, 
prescriber and pharmacist due to federal and state laws and regulations.  Controlled substance 
prescriptions must be dated and signed and in addition to the patient’s full name and address it 
must include the practitioner’s full name, address and Drug Enforcement Agency (DEA) 
 6
number.  The controlled substance prescription must also be “written in ink or indelible pencil or 
typewritten and must be manually signed by the practitioner” (DEA Pharmacist’s Manual, 2010).   
   
Insurance coverage/ method of payment 
 
Prescription transactions generally involve payment, which offers the pharmacist another 
opportunity to gather additional patient information.  There are two common mechanisms for 
payment based on whether or not the patient has insurance coverage for prescriptions.  Based on 
this, a patient either pays full price for the prescription at the pharmacy or pays some portion of 
the amount as determined by the insurance company. 
 Most prescriptions filled in the United States are covered by prescription drug insurance 
through a third party payor (Kaiser Family Foundation [KFF], 2005).  Patients have a 
relationship with an insurance company that acts as or hires a pharmacy benefits manager to 
handle the financial transaction of the medication for the patient.  The patient is usually 
responsible for a cost sharing co-pay and must follow the rules and formularies of the third-party 
payor.  Third-party prescription insurance can be categorized as private, government, or 
combination of the two.   
 Private prescription insurance can be obtained by individuals either directly from an 
insurance company or through an employer who may offer it as a benefit of employment.  
Private prescription insurance was involved in approximately 46% of national prescription drug 
expenditures in 2003 (KFF, 2005).  Government programs covered another 24% that same 2003 
year (KFF, 2005).  Many government programs, including Medicaid and SCHIP, are programs 
designed to help patients in a lower socioeconomic situations.  Then in 2006, Medicare, another 
government insurance program, offered prescription benefits for the nation’s Medicare eligible 
patients, which is made up of mostly elderly patients.  This system enrolled 22.5 million 
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beneficiaries in 2006 with an increase to 24.2 million beneficiaries in 2007 (KFF, 2007).  This 
government sponsored benefit is managed for patients by private third-party companies. Thus, 




 The patient is the core of any prescription, and it is a patient’s legitimate medical need 
that is the basis for a prescription (Fink et al., 2006).  Computerized record keeping enables a 
pharmacist in a pharmacy that has filled previously filled prescriptions for a patient to have 
access to those previous prescription records.  Such information is in essence additional 
information available to the pharmacist about the patient in addition to any information provided 




 The pharmacist also has information from the prescription item itself.  A written 
prescription can be delivered in person to a pharmacy by a patient or patient’s agent.  The 
prescription can be phoned in from a physician or physician’s agent to the pharmacist, faxed, or 
submitted electronically via secure means (Scott, 2005).  A traditional, written prescription 
generally contains both preprinted and handwritten information.  The preprinted information 
allows the pharmacist immediate access to the prescriber’s information, which can include the 
contact information for the physician including physician’s name, the name of the corresponding 
facility, address, phone number, and fax number.  Other possible preprinted details include the 
type of practice, the practice specialty, other physicians in the practice, and other locations 
owned by the same clinic.   
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 The handwritten parts of the traditional prescription are usually patient-related and 
indicate the date the prescription was written, the patient’s name and any appropriate 
demographic information such as birth date, the medication prescribed for the patient, the 
strength and quantity of the medication, directions for the patient, the number of refills indicated 
for the medication, and any specific directions for the pharmacist (Scott, 2005).   Prescriptions 
also can have computer-generated information in whole or in part that contains the same 




 In addition to demographic information provided by the patient, the pharmacist gathers 
information from the social interaction.  This occurs from traditional initial “first impressions” 
through to the end of the interaction from observations of patient behavior and conversations.  
Gender, age, race and ethnicity, and social class are the basic types of categories that are 
considered universally recognized upon initial human interaction (Fiske & Neuberg, 1990).  
According to the Fiske and Neuberg (1990) impression formation model, the first step when 
encountering others, is categorization.  Categorization occurs where the perceiver, in this case 
the pharmacist, places a basic category upon an individual based upon physical features such as 
age, gender, ethnicity, appearance or dress, verbal or written information providing a category 
label such as a business card, uniform, or name tag, a configuration of category-consistent cues 
that linked to past associations such as appearance driving a categorization of social class, or 
based on other information that arises during the interaction (Fiske & Neuberg, 1990).  This 
categorization is thought to occur “immediately upon encountering information sufficient for 
cuing a meaningful social category” (Fiske & Neuberg, 1990).  In other words, obtaining the 
information is part of the interaction.   
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Laws governing the ability to not fill 
 
 A pharmacist must abide by the various federal and state regulations that guide 
prescription dispensing in the United States.  Pharmacists stay informed of the laws that govern 
their profession.  Pharmacists have a duty to refuse to fill prescriptions that are not in compliance 
with state and federal laws and regulations.  The Durham-Humphrey Amendment was enacted in 
1951 and broadly defines the legal dispensing obligations of a pharmacist.  It established that 
prescription drugs can be dispensed:   
 
"…only (i) upon the written prescription of a practitioner licensed by law to administer 
such drug, or (ii) upon an oral prescription of such practitioner which is reduced promptly 
to writing and filed by the pharmacist, or (iii) by refilling any such written or oral 
prescription if such refilling is authorized by the prescriber either in original prescription 
or by oral order which is reduced promptly to writing and filed by the pharmacist (503(b) 
[21 USC § 353(b))." 
 
By setting criteria for determining which medications required a prescription not safe to use 
without medical supervision, this law established the two classes of drugs, over-the-counter and 
prescription drugs (Fink et al., 2006).   
 Included in the prescription class of medications are legend drugs and controlled 
substance medications such as opiates for pain and amphetamine and amphetamine-like 
treatments for Attention Deficit and Hyperactivity Disorder.  Controlled substances have stricter 
regulations than other drugs and are classified into schedules: I, II, III, IV, and V.  The smaller 
the number, the greater the DEA considers the medication’s abuse potential (DEA,  2010; Longo 
et al., 2000).  Non-schedule prescription medications are called legend drugs.  
 
Appropriate process of determining the validity of a prescription  
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 Validity can be based on either the legality of the prescription at a prima facie, judged at 
first impression, level or on a level of the clinical appropriateness of the therapy.  Prescriptions 
that are suspect as forgeries at a prima facie level should be verified with the prescribing 
physician.  The DEA warns: “The forger knows what information is needed on the prescription 
to make it appear authentic.  Pharmacists should be aware of the various kinds of forged 
prescriptions that may be presented for dispensing” (DEA, 2004). 
 Clinical appropriateness of therapy has a common sense element to it that is grounded in 
law.  It comes into play when a pharmacist has to decide if a prescription is within appropriate 
guidelines for a specific medication in treatment of a given condition.  The Federal 
Comprehensive Drug Abuse Prevention and Control Act of 1970, also known as the Controlled 
Substances Act (CSA), is the main federal law that regulates controlled substances (Abood, 
2011).  The CSA imposes limits on refills and the expiration date of the prescription and does not 
interfere with physicians’ medical decisions including choice of drug, duration, or prescription 
(21U.S.C.  §§801-907).  But it does limit the scope and legitimacy of the prescription:  
 
“A prescription for a controlled substance to be effective must be issued for a legitimate 
medical purpose by an individual practitioner acting in the usual course of his 
professional practice.  The responsibility for the proper prescribing and dispensing of 
controlled substances is upon the practitioner, but a corresponding responsibility rests 
with the pharmacist who fills the prescription.  An order purporting to be a prescription 
issued not in the usual course of professional treatment or in legitimate and authorized 
research is not a prescription” (Title 21 C.F.R.  1306.04). 
  
 The Act positions pharmacists at the center of determining the legitimacy of use based on 
treatment and scope of the prescriber’s practice.  A pharmacist must decide if the prescription is 
within the course of professional practice of the prescribing physician and that the prescription 
was written for a legitimate medical purpose (Joransen, 1993).  The DEA stresses that in order 
for a prescription to be valid, a prescription must be issued for a legitimate medical purpose by a 
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practitioner acting in their normal course of professional practice (DEA, 2010).  This 
determination must be made by pharmacists based on the information available at the time of 
filling the prescription.   
 
Ethics associated with filling or not filling 
 
 Pharmacists can also decide not to fill a prescription for other reasons such as ethical 
concerns.  The pharmacist’s right to refuse to dispense a prescription medication based on ethics 
has been addressed by pharmacy associations.  The American Pharmacists Association (APhA) 
has a pharmacy conscience clause that recognizes individual pharmacist’s right of refusal of 
particular medication based on moral objection and supports the patient’s right to access of 
medication.  The clause states: 
APhA recognizes the individual pharmacist’s right to exercise conscientious refusal and 
supports the establishment of systems to ensure patient access to legally prescribed 
therapy without compromising the pharmacist’s right of conscientious refusal (AJHP, 
1998). 
 
The American Society of Health Systems Pharmacists (ASHP) has a similar clause that balances 
a pharmacist’s moral considerations against a patient’s medication access rights:  
To recognize the right of pharmacists, as health care providers, and other pharmacy 
employees to decline to participate in therapies they consider to be morally, religiously, 
or ethically troubling; further, 
To support the proactive establishment of timely and convenient systems by pharmacists 
and their employers that protect the patient's right to obtain legally prescribed and 
medically indicated treatments while reasonably accommodating in a nonpunitive manner 
the right of conscience; further, 
To support the principle that a pharmacist exercising the right of conscience must be 
respectful of, and serve the legitimate health care needs and desires of, the patient, and 
shall provide a referral without any actions to persuade, coerce, or otherwise impose on 
the patient the pharmacist's values, beliefs, or objections. (AHSP, 2008). 
 
 Instances involving birth control illustrate the conscience clause issues.  Plan B 
(levonorgestrel) is a hormonal birth control medication. It contains a hormonal contraceptive 
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similar or the same chemical moiety as other hormonal contraceptives (Gee, 2006).  Plan B is 
different and controversial because of timing of the birth control effect. Plan B hormones prevent 
the implantation of a potentially fertile egg, while other hormonal birth control stop the release of 
eggs so fertilization cannot occur.  Citing conscientious objections over the interference of Plan 
B with human conception, some pharmacists have refused to fill prescriptions for Plan B based 
on ethical concerns (Gee, 2006).  These refusals have been met with physician activism and 
legislative action with a concern over patients rights (Gee, 2006).  Legislation has been proposed 
at a national level to require pharmacists to dispense any legal prescription (Guharoy & 
Noviasky, 2005).  The Plan B controversy and the response to it illustrate the unique position 
pharmacists hold in the access to medication process.  In an instance where a pharmacist refuses 
to fill on ethical beliefs, the proposed law would take precedence over any moral objections 
(Guharoy & Noviasky, 2005).   
 Information gathered during the prescription filling process will be processed by 
pharmacists and used to determine the validity of a prescription and ultimately influence whether 
a prescription is filled.  All of the information gathered and its relevance to the validity of a 
prescription is considered in the conjunction with the knowledge of the prescription that is being 
dispensed.  Some medications have properties and effects that make them more likely to be 
illegally sought by some individuals.  Given the nature of opioid medications and their addictive 
attributes, opioids is a class of medications that has legitimate patient uses and has properties that 




Conditions treated with opioids and the number of people associated with those illnesses  
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 Opioid analgesics are effective for treating pain (Portenoy, 1993; Trescot, et al., 2006) 
and have become some of the most prescribed medications in the United States (Kuehn, 2007).  
There were more than 100 million prescriptions in the year 2005 for combination drugs 
containing the opioid analgesic ingredient of hydrocodone (Kuehn, 2007).  Opioid analgesics are 




 Acute pain is classified as pain that is anticipated to be short lived with a recent onset  
(Zeller et al., 2008).  Treatment for acute pain using opioid analgesics is considered to be most 
common after surgical procedures and can be associated with a variety of diseases and medical 
conditions including arthritis, gout, sickle cell anemia, inflammatory bowel disease, and 
hemophilia (Portenoy, 1993).  Trauma and other medical events that are treated in an emergency 
room also warrant use of opioid analgesics (Thomas, 2007).  There are many other clinical 
scenarios where acute pain warrants treatment with opioids (Portenoy, 1993).   
 Opioid analgesics are considered to be initial therapy for acute pain (Zeller et al., 2008).  
Acute pain opioid analgesics are ideal if they have a rapid onset of action, short duration of 
action, minimum risk of respiratory suppression, and few drug interactions (Davis & Srivastava, 
2003).  Prescriptions for acute pain are usually short term depending on the patient and the 
condition.  Opioid prescriptions for the treatment of pain are considered a good clinical choice: 
“clinicians accept the use of these drugs for a period that is usually measured in days, during 






 Opioid analgesics are a widely accepted way to manage cancer-related pain.  Pain has 
been reported in upwards of 90% of cancer patients with 67% of the pain in patients with 
multiple pains related to the disease and 25% contributed to the treatment (Portenoy 1993; Davis 
& Srivastava, 2003).  Cancer-related pain can be acute or chronic.  Acute, cancer pain is usually 
related to procedures or therapies, postoperative pain, or pathology.  Chronic, cancer pain can be 
related to tumor associated pain syndromes or treatment associated pain syndromes (Portenoy & 
Lesage, 1999).   
 The mainstay approach to cancer-related pain is opioid, analgesic therapy (Portenoy & 
Lesage, 1999; Davis & Srivastava, 2003).  It is known that different people respond differently to 
different opioids, the goal is to find one medication or a combination of medications that 
balances the best analgesia with the fewest side effects for the individual (Portenoy & Lesage, 
1999).   
     It is not uncommon for cancer patients to be on more than one opioid at a time.  Combinations 
of different opioid analgesics are often used to treat pain in cancer patients.  Many patients are 
dosed with a long-acting opioid for continuous use that is supplemented with a prescription for a 
short-acting opioid dosed on an as needed basis for breakthrough pain (Davis & Srivastava, 
2003). 
 
Chronic non-malignant pain 
 
 Pain can also be chronic and non-cancer related.  Chronic pain is usually defined as pain 
that has persisted for at least three months following the usual healing time of an acute injury. It 
is considered pain that occurs in association with a non-healing lesion, or pain that recurs 
frequently over a period of months (Rosenblum et al., 2008).  There have been reports with 
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estimates that as many as one in three Americans suffers from chronic, nonmalignant pain 
(Portenoy, 1993). The actual number of patients suffering from chronic pain in the general 
population is thought to be high and difficult to ascertain (Rosenblum et al., 2008).  Newer 
published reports vary with some estimates at 10% of the population suffering from chronic non-
cancer related pain and some double that at 20% (Rosenblum et al., 2008). 
This includes patients who suffer from chronic, low-back pain and neck pain, of which 
60% still have symptoms 5 years after the first occurrence (Trescot et al., 2006).  Non-malignant 
pain affects the elderly commonly, with some researchers finding 45-80% of nursing home 
residents experiencing impaired mobility due to the pain (Davis & Srivastava, 2003).   
  
Opioids are a special case in medical therapy 
 
 Opioid analgesics are effective for treating pain (Portenoy, 1993; Trescot et al., 2006), 
and they also have very real negative potential consequences, such as abuse, tolerance and 
addiction (Longo, et al., 2000).  There are questions as to how to keep the balance in favor of 
optimal pain relief without potentiating the possible negative factors associated with opioid use.  
Pain treatment goals using opioids should include the alleviation of a patient’s pain while 
keeping the negative consequences in check.  Pain relief is the goal that is achieved through 
optimal use which could be interpreted as an increase in the amount of pain medications used.  
Increased use, though, also can be a signal that the opioid is being abused (Longo et al., 2000). 
 Abuse is defined as using a prescribed medication in a fashion other than what the 
prescriber intended (Longo et al., 2000).  This includes taking the drugs for recreational use, 
taking the drugs in larger amounts than those prescribed, taking the drugs at a greater frequency 
than prescribed or changing the route prescribed (Longo et al., 2000). 
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 Addiction differs from abuse.  The National Institutes of Health (NIH) defines addiction 
as “a chronic brain disorder characterized by the loss of control of drug-taking behavior, despite 
adverse health, social, or legal consequences to continued drug use” (NIH, 2000).  Longo et al. 
(2000) adds that addiction is a primary illness that represents itself with “physiologic 
homeostatic changes leading to tolerance,” with sensitization, withdrawal, and possible cognitive 
changes (Longo et al., 2000).  Greenwald and Narcessian (1999) point out that there is less than 
1% risk of iatrogenic addiction for patients who receive opioids for pain (Greenwald & 
Narcessian, 1999). 
 Tolerance presents in patients as a need to increase a dose or the dosing frequency to 
maintain the effectiveness of the medication without a discernible increase in the progression of 
disease (South & Smith, 2001).  Studies in cancer patients have shown opioid increases linked to 
disease progression rather than the onset of tolerance (South & Smith, 2001).  Greenwald and 
Narcessian (1999) contend that opioid tolerance is commonly misunderstood by healthcare 
professionals who believe that tolerance limits the long-term use of opioids in pain management 
(Greenwald & Narcessian, 1999).  This incorrect belief that it is common for decreasing 
analgesic effects requiring higher doses of medication is highlighted by the authors’ assertion 
that “clinically relevant tolerance to the analgesic effects of opioids seldom develops after the 
initial days or weeks of therapy” (Greenwald & Narcessian, 1999).   
 
Patients 
 Patients themselves are aware of the benefits of opioid therapy and are commonly aware 
of the potential risks of opioid therapy (Paice et al., 1998; Dawson et al., 2005; Palos et al., 
2004).  Some patients’ concern about the potential negative consequences of opioid use leads to 
the withholding of indicated proper treatment.  Patients’ concerns about tolerance and addiction, 
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both commonly known negative consequences associated with opioids, were studied as a barrier 
to cancer pain relief.  Paice et al. (1998) found a strong relationship between concern about 
addiction and concern about tolerance and higher reported pain.  Respondents used pain 
assessment tools to report their pain.  This was compared to their score results about their 
attitude towards opioids.  The study reported that fear of tolerance and fear of addiction both had 
an effect on pain intensity scales showing greater pain scores in those patients with higher fear of 
tolerance or addiction.  Patients in this study were more concerned about increased doses over 
time: “fear of tolerance showed to have a greater effect on pain intensity scores than did fear of 
addiction” (Paice et al., 1998).   
 In addition, Palos et al. (2004) surveyed adults about their pain medication use and found 
that women were likely to have attitudes deemed “conservative” which decreased the likelihood 
of taking pain medications when needed.  This conservative attitude included concerns about 
addiction and tolerance to analgesics including opioids (Palos et al., 2004).  Dawson et al. (2005) 
also found concerns about addiction and side effects were inversely related to a patient’s 
willingness to take opioid medication for pain.  The belief held by patients, “people get addicted 
to pain medications easily,” was a significant predictor of a patient being less willing to take an 
opioid if prescribed.  Interestingly the study also found patient’s beliefs about pain medication 
were formed in part from the care they received (Dawson et al., 2005).   
 
Physicians 
 Physicians have a wealth of clinical guidelines from which to choose that highlight 
opioids’ central role in treatment of pain.  But, it is the legal terminology “legitimate medical 
purpose” that holds the boundary of patients’ needs (Brushwood, 2005).  Physicians are aware of 
the dual nature of these medications and the need to address both the patients’ therapeutic needs 
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and the law.  Physicians have been shown to alter prescribing behavior based on concerns about 
opiate addiction.  A National Center on Addiction and Substance Abuse (CASA) study illustrates 
that physicians may change their prescribing patterns based on the fear of the risk of addiction of 
using opioid medication therapeutically (CASA, 2005).  Physicians also have concerns about law 
enforcement agencies misconstruing prescribing large amounts of opioid analgesics as 
overprescribing (CASA, 2005).   
 Efforts to educate physicians and to ease hesitance in prescribing resulted in the 
Federation of State Medical Boards (FSMB) issuing guidelines for the use of controlled 
substances for the treatment of pain (Trescot et al., 2006).  Also, the DEA clarified their position 
on using opioids for pain by deferring to and affirming practicing physicians’ knowledge about 




 Pharmacists are the gatekeepers of prescription medication and are responsible for 
keeping the integrity of the drug system intact (Bessell et al, 2002).  The unique position of the 
pharmacist results in a pharmacist having the role of determining the legitimacy of a prescription 
at a prima facie level, on an interpretive level deciding if the prescription is within the course of 
a physician’s professional practice and deciding if the prescription was written for a legitimate 
medical purpose (Joransen, 1993).  Several studies have illustrated the pharmacist’s response in 
this role to be one of reluctance in both filling and being prepared to fill prescriptions for opioid 
medications. 
 Gee and Fins (2003) found in their sample of palliative care experts that nearly three-
fourths of the respondents had patients who had encountered barriers to filling a legitimate 
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opioid prescription.  Patients were having trouble getting legitimate prescriptions for opioid 
analgesics filled at pharmacies.  This number (71.1%) was higher in comparison to the rate of 
patients claiming difficulty (34.2%) for filling legitimate non-controlled non-steroidal anti-
inflammatory drugs (NSAID) prescriptions (Gee & Fins, 2003).  Barriers that the patients could 
report included “‘patient inability to afford medications,’ ‘lack of insurance,’ ‘lack of medication 
benefit,’ ‘pharmacy barriers,’ ‘restrictive hospital or managed care formulary,’ ‘restrictive 
prescribing laws,’ or absence of economic, regulatory, and organizational barriers.”  Of the 
71.1% of the palliative care experts expressing patient’s claiming issues in obtaining controlled 
substances, 52.1% claimed the barriers were pharmacy-specific and included reasons such as 
pharmacies not stocking the needed medication, pharmacies not open due to restrictive hours, 
and pharmacists’ objections to filling the medications (Gee & Fins, 2003). 
 
Reluctance to Stock Opioid Medications 
 
 A study by Morrison et al. (2000) looked at the pharmacies’ stock of sufficient opioids 
for dispensing in ethnic minority communities.  For the study, opioids were divided into four 
categories as listed. 
1) Combination products for the treatment of moderate pain 
 
2) Short-acting opioid tablets for the treatment of breakthrough pain 
 
3) Short-acting opioids in liquid form for the treatment of severe pain in patients with 
swallowing difficulties  
 
4) Long-acting opioids for the extended treatment of severe pain 
 
The researchers then categorized pharmacy stock as complete, nearly complete, incomplete, or 
absent. Based on the criteria below (Morrison et al., 2000): 
Supplies were considered complete if the pharmacy had in stock an agent in each of the 
four medication categories nearly complete if the pharmacy had in stock sufficient 
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medication to treat a patient in moderate or severe pain – that is, a long-acting opioid, a 
short-acting opioid (tablet or liquid), and an opioid combination product; incomplete if 
the pharmacy lacked either a long-acting or a short-acting opioid preparation; and absent 
if the pharmacy did not carry any opioids but did stock other prescription medications. 
 
The results of the study showed that pharmacy respondents did not stock sufficient opioids and 
thus did not dispense certain opioid prescriptions.  The reasons given for not stocking opioids 
reported by the pharmacists sampled included among other reasons, the fear of fraud for illicit 
use and fear of robbery (Morrison et al., 2000).  This was in step with a 1986 and 2001 survey of 
pharmacies that did not stock sufficient opioids in minority neighborhoods that included fear of 
violence, added administrative work, along with a lack of demand as reasons for not carrying 
opioids for dispensing (Kanner & Portenoy, 1986; Kanner, 2001). 
 Green et al. (2006) found differences in opioid stock availability comparing across 
ethnically different pharmacies across Michigan.  Ethnic minority areas were less likely to have 
the necessary stock of opioids compared to pharmacies in predominantly white neighborhoods, 
regardless of the area’s median income and median age.  They also found that regardless of 
racial makeup of an area, lower income area pharmacies had stocking deficiencies for opioids 
compared to areas of higher income.  They also found variations based on the type of pharmacy.  
Independently-owned pharmacies were more likely to carry opioid medications and corporate or 
chain pharmacies were less likely to have sufficient stock.  Concerns of illicit opioid use along 
with low demand were cited as reasons for not carrying adequate opioid stock (Green et al., 
2006).  Greenwald and Narcessian (1999) also looked to quantify the resistance by pharmacists 
to stocking and dispensing opioids in their pharmacies.  They found that the type of drug 
influenced the likelihood of stocking.  The drug methadone was least likely to be stocked 
(Greenwald & Narcessian, 1999). 
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Previous relationship affects willingness to fill opioid medications 
 
 When examining the willingness of pharmacists to order out of stock medication for 
patients with opioid prescriptions, Kim et al. (2000) found the overwhelming majority would do 
so, but only if they had a previous relationship with either the patient or the physician or both.  
Only a third of the responding pharmacists would place an order for an out-of-stock opioid for an 
unfamiliar patient and doctor (Kim et al., 2000).   
 
Pharmacists’ knowledge and attitudes about opioid medications  
Pharmacists’ knowledge is lacking 
 Based on awareness and knowledge, a pharmacist’s behavior will differ in regard to 
treatment of opioid prescriptions.  A survey of pharmacists found that pharmacists who went 
through special training concerning the dispensing of controlled medications, preventing 
diversion of said products and identifying prescription drug addiction were more likely to check 
the dose on prescriptions to make sure the prescription doses were within regulations compared 
to those pharmacists who did not receive the special training (CASA, 2005).   
 Greenwald and Narcessian (1999) assessed pharmacists’ knowledge and attitudes 
regarding the use of opioids in certain situations.  Cancer patients and chronic nonmalignant pain 
patients were presented in different scenarios to pharmacists to assess their knowledge of the 
legitimacy based on clinical appropriateness and legality of specific dispensing of opioid 
prescription scenarios.  In interpreting the legality and legitimacy of dispensing opioids in the 
scenarios, respondents showed they were lacking the knowledge of law and clinical practice to 
correctly decide based on these factors.  The legitimacy and legality of a prescription were 
misclassified by some pharmacists in all scenarios.  The most dramatic case showed only 3% of 
the respondents believed the legality and clinical appropriateness of a legitimate prescription 
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written for a patient with chronic nonmalignant pain and a history of opioid abuse (Greenwald & 
Narcessian, 1999).   
 Joranson and Gilson (2001) also found pharmacists’ knowledge to be lacking in certain 
situations regarding opioid pain medications.  They found this despite finding a majority of the 
responding pharmacists (87%) were confident in their ability to recognize a diversion attempt 
where a person was attempting to obtain controlled substances from a pharmacy for other than 
legitimate medical purposes.  They found varying percentages of responding pharmacists to be 
unaware of the legal and legitimate dispensing of opioid medications depending on the scenario 
presented. A legal and legitimate scenario involving a cancer patient with chronic pain, who also 
had a history of opioid abuse revealed that only 64% of the pharmacists respondents expressed 
confidence in the validity of a prescription for this patient.  This is in contrast to the 
overwhelming 93% of respondents who were confident in the legality and medical legitimacy of 
dispensing opioids for more than several months for pain patients with a malignancy and history 
of opioid abuse (Joranson & Gilson, 2001). 
For the nonmalignant pain scenarios, 57% of respondents expressed confidence in 
dispensing opioids for an extended period as legal and accepted practice. But only 8% of the 
pharmacists viewed the prescribing and dispensing of opioids for more than several months to a 
patient with chronic nonmalignant pain and a history of opioid abuse as legal and acceptable 
medical practice (Joranson & Gilson, 2001). 
The legal and legitimate scenarios in the Joranson and Gilson (2001) study were similar 
to the Greenwald and Narcessian (1999) study that had patients with previous substance abuse 
issues included in some of the scenarios compared against scenarios with patients with no 
substance abuse.  All the scenarios presented in both studies were considered to be both legal and 
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legitimate as presented by the researchers and should have arguably had 100% confidence rate as 
valid by responding pharmacists (Joranson & Gilson 2001). 
 Doucette et al. looked at pharmacists’ knowledge and practices in regard to cancer pain 
management and found pharmacists to have a knowledge deficit in some areas.  Less than 50% 
had correct answers when responding to the statements that involved tolerance risk, risk of 
addiction, respiratory depression, and the inevitability of cancer pain (Doucette et al., 1997).  
The results of these studies leave the impression that information other than legal and clinical 
factors were being used to make the decisions about dispensing opioid prescriptions. 
 
Strategies available for pharmacists to use when filling  
 There are published strategies to help pharmacists make better decisions about legitimate 
prescriptions when filling prescriptions.  The DEA publishes a handbook for pharmacists with 
specific recommendations for handling potentially illegitimate prescriptions.  Included in those 
recommendations are descriptions of characteristics of forged prescriptions: 
“Prescription looks ‘too good’; the prescriber’s handwriting is too legible; quantities, 
directions or dosages differ from usual medical usage; prescription does not comply with 
the acceptable standard abbreviations or appear to be textbook presentations; prescription 
appears to be photocopied; directions written in full with no abbreviations; prescription 
written in different-color inks or written in different handwriting; or the prescription has 
apparent erasure marks.” (DEA, 2004) 
 
Also, criteria that may indicate that a prescription may not have been issued for a legitimate 
medical purpose: 
 
o “The prescriber writes significantly more prescriptions (or in larger quantities) 
compared to other practitioners in your area. 
o The patient appears to be returning too frequently. 
o Prescription, which should last for a month in legitimate use, is being refilled on a 
biweekly, weekly or even a daily basis. 
o The prescriber writes prescriptions for antagonistic drugs, such as depressants and 
stimulants, at the same time.  Drug abusers often request prescriptions for ‘uppers 
and downers’ at the same time.   
o Patient appears presenting prescriptions written in the names of other people. 
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o A number of people appear simultaneously, or within a short time, all bearing 
similar prescriptions from the same physician.   
o Numerous ‘strangers,’ people who are not regular patrons or residents of your 
community, suddenly show up with prescriptions from the same physician” 
(DEA, 2004). 
 
 Brushwood and Carlson took the pharmacist’s role as healthcare professional that 
includes the function of verifying facially suspect prescriptions and summarized a framework 
recommended by the DEA to address “dubious” prescriptions (1991).  The framework uses a 
decision tree that starts at the encounter of a “dubious” prescription and offers strategies for 
correctly addressing the issue.  The step-by-step instructions include the facial examination of a 
prescription, correspondence with the prescribing physician, and interviewing the patient for 
further information (Brushwood and Carlson 1991).  The steps are intended to enable the correct 
handling of a prescription where the validity is doubted on a prima facie basis, in other words, 
this system provides a step-by-step basis to ensure that a valid prescription gets filled and that an 
invalid one does not.   
 The question remains as to what information is being considered that would initiate the 
pharmacist questioning the legitimacy of a prescription.  There are resources available to 
pharmacists that offer suggestions to aid in determining the validity of a prescription.  
Brushwood (2001) offers a stepwise approach pharmacists could use when determining the 
legitimacy of a prescription (Brushwood, 2001).  This systematic approach includes several steps 
with each subsequent step increasing the likelihood that further investigation of the validity of a 
prescription will be necessary.   
 Brushwood outlined the first step as “irrelevant factors.”  They include off-label uses, 
aggressive demands, dose and frequency increases (2001).  These factors include patient 
behaviors such as aggressive demands and frequency increases.  They also include prescription 
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factors such as dose increases and off-label uses.  The factors alone, as Brushwood notes, do not 
indicate by themselves an illicit prescription (Brushwood 2001). 
 “Suspicion factors” were outlined as the next step in the process and were a key to start 
suspecting the validity of the prescription.  These included patient behaviors of distracting 
behavior, frequent loss of medication by the patient and a patient requesting opioids only on a 
multi-medication prescription (Brushwood, 2001).  Other prescription factors in this step 
included seeing the same drug from many prescribers (Brushwood, 2001). 
 Following the “suspicion factors,” “confirmation factors” were described as a definite 
sign that a prescription was more than likely illegal.  In this step, a patient refuses prescriber 
inquiry, refuses partial supply, or refuses the pharmacy a copy of their identification 
(Brushwood, 2001).  These patient behaviors according to Brushwood (2001) are telltale signs of 
an illicit prescription and the pharmacist should take appropriate action.    
 The final steps in Brushwood’s system are the “determinative factors.”  These include a 
known past forgery from a patient or the knowledge of street drug use by the patient 
(Brushwood, 2001).  A pharmacist is encouraged to be dubious of prescriptions associated with 
these factors.  Brushwood concludes that the suggested process is by no means conclusive and 
adds: “This step-wise approach is offered only as a suggestion for a process that might be 
effective in helping pharmacists do their jobs well” (Brushwood, 2001, p. 115). Brushwood’s 
conclusion highlights the pharmacist’s reliance on available and imperfect information in 
deciding the legitimacy of a prescription (Brushwood, 2001).  The decision process for 
determining legitimate prescriptions is made by pharmacists.  The information that is available to 
pharmacists in guiding them on the legitimacy of prescriptions still must be used by the 
pharmacist in making a decision.   
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Summary  
 Patients experience barriers to getting opioids filled in pharmacies.  Studies show 
sometimes the medications are not available in certain areas and that this availability deficiency 
is more likely to occur in low income neighborhoods.  Studies show legitimate prescriptions are 
sometimes deemed invalid by pharmacists and also pharmacists have a reluctance to fill valid 
prescriptions in certain situations, as defined by prior history and patient presentation.  These 
barriers and the reluctance to fill prescriptions for opioids and stock opioids, and an inability to 
completely determine the legitimacy of controlled substance prescriptions suggests that 
pharmacists may not always be using situationally defined, objective criteria to make these 
decisions.  It raises the question as to how pharmacists are using the information available to 
them when making decisions to fill opioid medications. 
 
Research Question: What information do pharmacists find relevant when deciding the 
validity of an opioid prescription? 
 
Of all the available information available to a pharmacist, what information does a 
pharmacist rely on when the decision is made to either fill a prescription or take another route of 
action?  In making decisions about the validity of a prescription, pharmacists are likely to use the 
information available at the time of filling the prescription.  As discussed, there are 
recommendations as to what information should be used and how that information can help to 
determine the veracity of a prescription.  What is not known is what information pharmacists 
consider relevant in determining whether a prescription is valid or not.   
 
Study Objectives 
Objective 1: To determine the level of relevance pharmacists attribute to specific information 
available during the prescription filling process when determining the validity of a prescription. 
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Objective 2: To determine if pharmacists attribute different levels of relevance to specific 
information available during the prescription filling process when determining the validity of a 
prescription of a controlled versus non-controlled prescription. 
 
Hypotheses 
H1: Pharmacists attribute greater relevance to irrelevant factors when deciding the validity of a 
prescription for a prescription for CIII medications than to non-scheduled prescriptions.  
 
H2: Pharmacists attribute greater relevance to suspicious factors when deciding the validity of a 
prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
 
H3: Pharmacists attribute greater relevance to confirmatory factors when deciding the validity 
of a prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
 
H4: Pharmacists attribute greater relevance to determinative factors when deciding the validity 
of a prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
 
H5: Pharmacists attribute greater relevance to DEA factors when deciding the validity of a 













Licensed practicing pharmacists are experts in the information sought when filling 
prescriptions and determining their validity.  It can be argued that any licensed practicing 
pharmacist has the ability to assess the validity of a prescription offered by a patient for filling 
and dispensing.  It is reasonable to ask a licensed practicing pharmacist to rate the relevance of a 
particular piece of information associated with a prescription scenario as it relates to prescription 
validity.   
A national list of licensed community pharmacists was purchased from a healthcare 
database service for use in this study. Then a non-probability, random sample of pharmacists 
from the list was selected to participate in the study. 
 
Sample size 
Based on a medium effect size and using G-Power software, an effect size of 0.25 was 
estimated, as recommended by Cohen (1992), with an alpha 0.05, at a power of 0.95.  The 
suggested sample size is 194, or 97 per group (Faul & Erdfelder, 1992).  Based on this, a sample 
size of 105 per group would be sufficient and accommodate possible liberal effect-size 
estimation. To ensure that 105 pharmacists per group completed the study, it was estimated that 
surveys would need to be sent to 2100 pharmacists (i.e., 1050 per group).  This would be a 
response rate of 15%.  Previous response rates of community pharmacists were sought to predict 
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the response rates for this study.  The response rates for participants in a web-based survey to 
assess the attitudes toward and factors affecting implementation of medication therapy 
management services by community pharmacists in Texas garnered an 11.8% response rate 
(MacIntosh et al., 2009).  Another web-based survey of community pharmacists assessed the 
knowledge of and attitudes toward oral chemotherapy and was able to capture a 22.5% response 
rate (O'Bryant & Crandell, 2008).  Based on these, a conservative 15% response rate seemed 
reasonable.   
 
 
Survey Instrument Design 
The objectives of this study were met by creating a measure to assess the relevance that 
pharmacists assign to various pieces of information used to assess the validity of a prescription in 
a given scenario.  Each pharmacist was asked to read a prescription scenario and then answer 
questions about the validity of the prescription.  The scenarios and survey questions are shown in 
Appendix A.   
Pharmacist participants were asked to rate the relevance of each specific piece of 
information as it relates to prescription validity in the scenario using a 7 point Likert-type scale.  
Relevance is defined as the information being assessed having a sensible or logical connection to 
the matter at hand (Merriam-Webster, 2009).  In this study the connection would be with the 
validity of the prescription. 
 The information presented for relevance was gathered from information available to a 
pharmacist at the time of filling as presented in the previous chapter.  Also, the DEA publishes a 
handbook for pharmacists “Pharmacist’s Manual: An Information Outline of the Controlled 
Substances Act of 1970” (2004).   
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The DEA has guidelines for pharmacists to use in determining the validity of 
prescriptions (DEA, 2004).  Specifically, the DEA in its publication “Pharmacists Manual,” 
offers several characteristics of a fraudulent prescription that a pharmacist should look for in 
assessing validity.  
Additionally, the DEA stresses that in order for a prescription to be valid, a prescription must 
be issued for a legitimate medical purpose by a practitioner acting in their normal course of 
professional practice.  They offer these criteria in guidance of recognizing prescriptions that may 
have not been written for a legitimate medical purposes: 
 The physician writes significantly more prescriptions larger quantities compared to other 
practitioners in the area. 
 The patient appears to be returning too frequently and requesting early refills. 
 The prescriber writes prescriptions for antagonistic drugs, such as depressants and 
stimulants, to be taken at the same time. 
 Patient appears presenting prescriptions written in the names of other people. 
 A number of people appear simultaneously, or within a short time, all bearing similar 
prescriptions from the same physician. 
 Numerous "strangers," people, who are not regular patrons or residents of your 
community, suddenly show up with prescriptions from the same prescriber. (DEA, 2004) 
 
Also, there is guidance available to pharmacists through journals and State Board of 
Pharmacy newsletters, including publications authored by Brushwood (2002) that offer a 
stepwise approach to determining fraudulent prescriptions.  Brushwood (2002) classified 
information available to a pharmacist in a proposed, stepwise manner and labeled the 
information as irrelevant factors, suspicious factors, determinative factors, and confirmatory 
factors: 
Step 1: Irrelevant Factors 
 Off-label use. 
 Aggressive demand. 
 Dose/frequency increases. 
 
Step 2: Suspicion Factors 
 Distracting behaviors. 
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 Frequent loss. 
 Only opioids. 
 Same drug, many prescribers 
 Always cash and always brand. 
 
Step 3: Confirmation Factors 
 Refuses prescriber inquiry. 
 Refuses partial supply. 
 Refuses to permit photocopying of identification. 
 
Step 4: Determinative Factors 
 Past forgery. 
 Knowledge of street drug use. (Brushwood, 2002) 
 
Available information at the time of filling, including those criteria outlined by the DEA (2004) 
and by Brushwood (2002), was presented to pharmacists as possible information pieces to 
consider.  In addition, information of past known opioid addiction (Joranson & Gilson, 2001; 
Greenwald & Narcessian, 1999) was presented as a factor to consider. Additionally, information 
that might be available but not captured in the mentioned categories was presented for 
consideration.  The pharmacists were asked to determine the relevance of each specific piece of 
information when considering the validity of a prescription.  Participants were divided 
alphabetically by last name and asked to consider only one type of medication and one piece of 
information at a time.   
Participants were asked to consider either a legend drug (amoxicillin) or a schedule III 
controlled substance opioid pain medication (hydrocodone/acetaminophen combo) in a 
prescription scenario.  The drug Soma® (carisoprodol) was also included for consideration for a 
third group of participants.  At the time of the proposal of the study, carisoprodol was a legend 
drug in all but two states.  It was suggested that carisoprodol be added as a third group because 
of its mainly non-controlled status and its abuse potential.  
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 Individual participants were asked to consider different pieces of information for 
relevance for the legend drug, the scheduled drug, or the carisoprodol.  For example, a 
participant was asked to consider the relevance of an irrelevant factor for an amoxicillin 
prescription, then the relevance of a determinant factor for an amoxicillin prescription, then the 
relevance of a DEA factor for an amoxicillin prescription, and so on, for different pieces of 
information.   
The demographics of responding pharmacists was collected for analysis including 
gender, age, practice zip code, years in practice, degree type (PharmD., B.S.), and the years since 
last practice degree was obtained.  Main practice type (independent retail, chain retail, hospital, 
institutional, other) and affirmation of community pharmacy practice was collected to ensure the 
participants practice community pharmacy as pharmacists. 
To determine face validity of the survey instrument, three pharmacists who practice in 
community pharmacy were asked to review the survey instrument.  It is important to assess face 
validity to ensure the measures adequately represent all facets of the concepts being measured.  
The survey instrument was modified based on their comments for spelling and grammar 
modifications. 
Additionally, the survey instrument was pre-tested by administering it in its electronic 
version to five pharmacists.  The pre-test was important in determining the length of time 
required to complete the survey and to assess the clarity of instructions and items.  Based on the 








The prescription medications in the scenarios were presented as a prescription for a non-
scheduled legend drug (amoxicillin), a schedule III medication (hydrocodone/acetaminophen 
combo), and Soma® (carisoprodol).  A three-group design was needed to test study hypotheses.  
The survey instrument with scenarios was reviewed by the IRB of The University of Mississippi 
before commencing the data collection.  Participant incentives were not used. 
An invitation to participate in an Internet survey was distributed to the sample 
pharmacists using a third-party vendor who distributed requests by email. The Internet survey 
was hosted online by SurveyMonkey™.  By email, the sampled pharmacists received an 
invitation to participate along with a link to the survey.  Respondents were assigned to one of the 
three groups by asking them to click on one of three links based on the starting letter of their last 
name.  The survey was fielded for one week, after one week a reminder email including the 
survey link was sent out to the sampled pharmacists thanking them for their participation or 
encouraging them to participate if they have not done so.  Data collection was closed at four 
weeks after the initial email. 
 
Analysis 
Data was analyzed using the Statistical Package for Social Sciences (SPSS) software 
(Chicago, IL).  Response rates were calculated.  A sample description using frequencies and 
percentages or means as appropriate was determined.  Descriptive statistics, including mean and 
standard deviations were calculated for all measures.  Reliability of measures was assessed by 






Sample Description and Descriptive Statistics 
A total of 2,328 pharmacists were sent email requests to participate in the survey.  Of 
those, 126 of the email messages were returned as undeliverable.  The undeliverable emails 
included both hard bounces (an attempt at an email address where nothing was delivered due to a 
bad email, domain, and connection or configuration problem) and soft bounces (sent to a valid 
address but were filtered or rejected by the intended address).   
Of the 2328 pharmacists emailed there were 157 responses (6.77% response rate), 
considering undeliverable emails, the usable response rate 7.7% (157/2202).   
Of the 157 respondents that accessed the survey, 104 of the surveys were retained for 
analysis.  Twenty-three of the 157 that accessed the survey were excluded because they were not 
pharmacists. Thirty surveys were opened and started but there were no responses making them 












































4 0 2 5 0 6 26 1 44 
Carisoprodol 
group 
4 4 0 2 1 5 15 0 31 
Hydrocodone
/Apap group 
1 0 0 4 0 12 12 0 29 
Total 9 4 2 11 1 23 53 1 104 
 Indep. = Independent  Apap = Acetaminophen 
Table 1 provides a description of the sample across each of the three groups (amoxicillin, 
carisoprodol, hydrocodone/apap) and as a whole.    More than half of the pharmacist respondents 
identified themselves as practicing in single store independent pharmacies.  The second largest 
group identified themselves as multiple store independent pharmacists.  There were also 
institutional outpatient pharmacists, institutional inpatient pharmacists, grocery store pharmacy 
pharmacists, mass-merchandiser chain pharmacists, and traditional chain pharmacists.  There 
were significant differences in practice type distribution across the groups with a Pearson Chi-
Square of 26.17 (p = .025).  Additionally there were nine respondents that identified their main 
practice setting as “other.”   These included various specialty pharmacies (Table 2).  There were 
no significant differences in other practice type distribution across the groups with a Pearson 
Chi-Square of 23.96 (p = .464).   
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When asked about the number of years (rounded to the nearest whole number) they have 
been in pharmacy practice, the respondents answered with mean of 23.2 years in practice (Table 
3).  There were 44 female respondents and 59 male, one respondent did not respond to the 
gender demographic question.  There were no significant differences in gender distribution 
across the groups with a Pearson chi square of 2.69 (p value= .669) (Table 4).In the sample, there 
were a total of twenty-six pharmacists who reported having PharmD practice degrees. There 
were no significant differences in PharmD distribution across the groups with a Pearson Chi-
Square of 2.492 (p = .288) (Table 5). Eighty respondents reported having Bachelor-level practice 
degrees reported, and there were no significant differences in Bachelor Degrees distribution 
































































Amoxicillin 39 0 1 0 1 0 0 0 1 1 1 0 0 44 
Carisoprodol 25 1 0 1 0 0 1 1 0 0 0 1 1 31 
Hydrocodone/ 
Apap 
28 0 0 0 0 1 0 0 0 0 0 0 0 29 




Table 3: Years in Practice 
GROUP N Mean Std. Deviation 
Amoxicillin 44 24.07 10.98 
Carisoprodol 31 23.74 14.05 
Hydrocodone/Apap 29 21.31 11.71 
TOTAL 104 23.20 12.11 
 
Table 4: Gender of Respondents 
Group No Answer Female Male Total 
Amoxicillin 1 16 27 44 
Carisoprodol 0 15 16 31 
Hydrocodone/Apap 0 13 16 29 
Total 1 44 59 104 
 
 
Table 5: Pharmacy Practice Degree 
Group/ Type B.S. Degree Pharm D 
Amoxicillin 37 8 
Carisoprodol 23 8 
Hydrocodone/Apap 20 10 
TOTAL 80 26 
 
Hypotheses Testing 
To test individual hypothesis, the items (questions) were grouped into the factors they 
represented in the literature.  The means of item responses were computed.  Items were grouped 
into the factors they represent and the response means computed for each category.  Means and 
standard deviations for scales in each of the three groups are provided in Table 7.  The reliability 
of each factor was assessing using Cronbach’s alpha, as presented in Table 8. 















Mean 3.71 3.82 6.08 5.15 5.49 2.57 
SD 1.22 1.46 1.24 1.32 1.13 0.99 
Group 2 
Carisoprodol 
Mean 4.88 5.67 6.56 6.03 5.09 3.65 
SD 1.67 1.09 0.79 0.94 1.00 1.10 
Group 3  
Hydrocodone/apap 
Mean 4.79 5.73 6.16 6.08 5.94 3.44 
SD 1.22 1.08 1.35 1.20 0.91 0.89 
*Based on a 1-7 scale where 1=not relevant  and 7= very relevant 
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Table 7: Reliability Results – Cronbach’s Alpha 
Factors Item 
Means 
Min Max α Item Numbers 
Irrelevant 4.359 3.779 5.117 .574 1, 2, 22 
Suspicious 4.906 4.356 5.712 .857 3, 4, 5, 24, 25 
Confirmatory 6.247 5.740 6.673 .716 6, 7, 8 
Determinative 5.671 4.760 6.583 .558 9, 23 
DEA 5.739 3.490 6.750 .937 19, 26, 27, 28, 29, 30, 31, 
32, 33, 34, 35, 36, 37, 38, 
39 
Other 3.136 1.563 5.096 .905 10, 11, 12, 13, 14, 
15,16,17,18,20, 21, 40, 
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Group factor means were compared using MANOVA.  Two groups of medications 
(amoxicillin and hydrocodone/apap) were included in the hypotheses testing.  The amoxicillin 
group and the hydrocodone/apap group were compared in pair-wise fashion to determine if the 
differences in response means represented significant differences.  A significant difference 
(Hotelling’s Trace = 40.298, F = 443.277, p < .05) was found between the two groups.  
Significant differences, at the .05 level, were found in the response means between the 
amoxicillin and hydrocodone/apap groups in Irrelevant Factors, Suspicious Factors, 
Determinative Factors, and Other Factors (See Table 9).  A summary of findings related to 
hypothesis testing is as follows: 
Table 8: Average Difference between groups on each factor 
 
(* mean difference significant at the .05 level) 
 
 Mean Difference between 
Amoxicillin & Hydrocodone groups 
Significance 
(at .05 level) 
Irrelevant Factor Mean 1.088 * .000 
Suspicious Factor Mean 1.909 * .000 
Confirmatory Factor Mean 0.078 .801 
Determinative Factor Mean 0.931 * .003 
DEA Factor Mean 0.454 .074 
Other Factor Mean 0.867 * .000 
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H1: Pharmacists attribute greater relevance to irrelevant factors when deciding the validity of a 
prescription for a prescription for CIII medications than to non-scheduled prescriptions.  
H1 supported.  
Pharmacists in the sample attributed more relevance to irrelevant factors when considering the 
validity of a hydrocodone/apap prescription than when considering the validity of an amoxicillin 
prescription. 
 
H2: Pharmacists attribute greater relevance to suspicious factors when deciding the validity of a 
prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
H2 supported. 
Pharmacists in the sample attributed greater relevance to suspicious factors when deciding the 
validity of a prescription for hydrocodone/apap than when considering the validity of an 
amoxicillin prescription. 
 
H3: Pharmacists attribute greater relevance to confirmatory factors when deciding the validity 
of a prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
H3 not supported. 
Pharmacists in the sample indicated that the confirmatory factors had the same relevance 
whether they were considering the validity of the amoxicillin prescription or the 
hydrocodone/apap prescription. 
 
H4: Pharmacists attribute greater relevance to determinative factors when deciding the validity 
of a prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
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H4 supported. 
When evaluating the validity of a hydrocodone/apap prescription, pharmacists in the sample 
attributed greater relevance to determinative factors than when considering the validity of an 
amoxicillin prescription. 
 
H5: Pharmacists attribute greater relevance to DEA factors when deciding the validity of a 
prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
 H5 not supported. 
Pharmacists in the sample considered DEA factors to have the same amount of relevance when 






Pharmacists were asked to rate the relevance of various pieces of information (or factors) 
as they related to the validity of the prescription. They were given scenarios that represented 
potential information available to pharmacists at the time of filling.  Regardless of the scenarios, 
pharmacists used confirmatory, determinative, and DEA factors to determine the validity of a 
prescription.  Irrelevant, suspicious, and other factors were considered less often.  Although there 
are certain pieces of information used more commonly than others, pharmacists do consider 
different information depending on the prescription.  
Three of the five hypotheses were supported, which indicates that pharmacists did deem 
certain types of information (irrelevant information, information that can be deemed suspicious 
and determinative information) to more relevant when filling a prescription for a controlled 
substance than for an antibiotic.  This indicates that controlled prescription medications are held 
to a different standard when it comes to assessing their validity; and the different standard seems 
to manifest in the assessment of irrelevant, suspicious, and determinative factors.  Two of the 
hypotheses were not supported indicating that pharmacists in the sample are likely to consider 
the DEA factors and confirmatory factors to hold the same amount of relevance regardless of 
whether the prescription is a controlled substance or an antibiotic.  Therefore, factors that the 
DEA promotes as being relevant and factors that are published to be confirmatory in the 
assessment of a prescription appropriately carried the same level of relevance to the pharmacists 
in the sample. 
Irrelevant Factors 
H1: Pharmacists attribute greater relevance to irrelevant factors when deciding the 
validity of a prescription for a prescription for CIII medications than to non-scheduled 
prescriptions.  
H1 supported.  
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The patient is aggressive in demanding the prescription immediately [irr] 
The dose of the prescription seems high [irr] 
The prescription was written for an off-label use [irr] 
(Cronbach’s α = .574)   
 
There was a significant difference in the relevance placed upon the grouping of 
information titled irrelevant factors for the pharmacists considering the validity of the 
controlled medication prescription when compared with the relevance placed by pharmacists in 
the group presented a non-scheduled medication.  Published guides indicate that these factors are 
possibly used for screening potential problem prescriptions despite the fact that they are not 
directly relevant to the validity of the prescription.  This raises the question as to how 
pharmacists ultimately use this information in deciding whether to fill a prescription for a 
patient.  Research findings indicate that pharmacists are less willing to fill controlled substance 
prescriptions (Greenwald & Narcessian, 1999; Kim et al., 2000; Gee & Fins, 2003).  The 
findings supporting hypothesis 1 indicate that this reluctance may manifest in the assessed 
relevance of irrelevant information – information that is not directly related to the validity of the 
prescription and may not be an appropriate indicator or surrogate for validity assessment. 
Pharmacists were asked to consider each piece of information independently.  Therefore, 
it is not clear whether this information alone would lead to a patient not receiving medication.  
Yet, it does seem that pharmacists will consider this information relevant and that is a important 
step toward those factors being included in their decision to fill or not fill a given prescription. 
Suspicious Factors 
H2: Pharmacists attribute greater relevance to suspicious factors when deciding the 
validity of a prescription for a prescription for CIII medications than to non-scheduled 
prescriptions. 
H2 supported. 
Patient lost the medication and this is a replacement [sus] 
This medication accompanies another medication and the patient doesn’t want the other 
filled [sus] 
From the profile, you see that the patient has had this medication before from another 
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prescriber [sus] 
The patient refuses generic substitution [sus] 
The patient ask that the prescription not be run on their prescription drug insurance [sus] 
(Cronbach’s α = .857) 
 
 
When the pieces of information named suspicious factors was presented to the two 
groups of pharmacists, again the relevance of the information by the group given the controlled 
scheduled medication stimulus was rated higher than that compared to the group given the non-
controlled medication.  While these factors may lead a person to be suspicious, they should have 
the same relevance regardless of prescription.  The fact that pharmacists in this study indicate a 
greater relevance to these factors for the controlled prescription indicates that there may be a link 
between pharmacists assessed relevance of these factors and the reported difficulty that patients 
have in having filling valid controlled prescription medications. 
 These patient behaviors seem to have more relevance to pharmacists when filling a 
controlled substance prescription than when filling an antibiotic.  From the present study, it is not 
clear whether this relevance is simply a clue that would drive pharmacists to consider other, 
more appropriate information, or whether it will change the likelihood that a prescription will be 
filled or not. The differential relevance of these factors, as compared to an antibiotic, do further 
support the likelihood that controlled substance medications are held to a different level of 
scrutiny than prescriptions for antibiotics. 
Confirmatory Factors 
H3: Pharmacists attribute greater relevance to confirmatory factors when deciding the 
validity of a prescription for a prescription for CIII medications than to non-scheduled 
prescriptions. 
 
H3 not supported. 
 
The patient refuses to let you call the doctor to verify the prescription [conf] 
The patient refuses a partial fill while you verify the prescription [conf] 
The patient refuses to show you identification [conf] 
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(Cronbach’s α = .716) 
 
 For the information deemed confirmatory factors, there was no significant difference 
between the pharmacists shown the controlled scheduled medication scenario and the 
pharmacists in the non-controlled medication group.  This may seem to go against the trend seen 
from the previous factor groups, but the means of both groups are toward the higher relevance 
side of the 7 point scale (non-controlled group mean= 6.08, SD=1.24;  controlled group 
mean=6.16, SD=1.35).  This indicates that there were no significant differences between the two 
groups, and both groups placed a high level of relevance equally upon the pieces of information.  
Perhaps, the behaviors presented in this group might be egregious enough that they 
transcend the controlled versus non-controlled nature of the question posed.  The “patient 
refuses” statement that starts each item puts the patient directly between the pharmacist and their 
duties.  This in itself might bring the validity of any given prescription into question, no matter 
the medication. The patient’s refusal behavior may also indicate an unwillingness to actively 
participate in assisting the pharmacist to properly do her job.  As a result, this refusal of the 
patient may call into question the validity of the prescription regardless of class of medications 
being dispensed.   
Determinative Factors 
H4: Pharmacists attribute greater relevance to determinative factors when deciding the 




There is a note in the profile that this patient has presented a forged prescription before [det] 
The patient uses “street drug” terminology to describe another medication he is taking [det] 
(Cronbach’s α = .558) 
 
Hypothesis 4 was supported. This again gives a significant difference in pharmacists 
assigning relevance of the information in determining validity of a prescription between the 
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groups that did and did not get the controlled drug as the differentiating medication.  Pharmacists 
thought these two items, considered the determinative factors in the literature, to be more 
relevant for a controlled medication than for a non-controlled medication.  These two items 
speak directly to potential drug abuse, with a forgery mentioned in one and “street drug” 
mentioned in the other.  It would seem almost obvious that they would not warrant the same 
level of relevance for a non-controlled amoxicillin prescription than for a controlled 
hydrocodone medication. 
This finding seems to indicate that pharmacists will consider a patient’s past behavior to 
be relevant to the validity of their future prescriptions.  It also seems to indicate that pharmacists 
deem this past behavior to be more relevant to controlled substance prescriptions than 
amoxicillin prescriptions. 
DEA Factors 
H5: Pharmacists attribute greater relevance to DEA factors when deciding the validity of 
a prescription for a prescription for CIII medications than to non-scheduled prescriptions. 
 
H5 not supported. 
Quantities differ from usual medical usage [dea] 
The prescriber has very clear and legible handwriting. [dea] 
Directions differ from usual medical usage[dea] 
Dosages differ from usual medical usage [dea] 
Sig codes do not match acceptable standard abbreviations [dea] 
Prescription appears to be photocopied[dea] 
Prescription directions are written in full with no abbreviations [dea] 
Prescription written in different-color inks [dea] 
Prescription written in different handwriting [dea] 
There are apparent erasure marks on the prescription [dea] 
A number of people appear simultaneously, or within a short time, all bearing similar      
prescriptions from the same physician [dea] 
Numerous "strangers," people, who are not regular patrons or residents of your 
community, suddenly show up with prescriptions from the same prescriber [dea] 
The prescription is written for significantly larger quantities compared to other 
practitioners in the area [dea] 
The patient appears to be returning too frequently [dea] 
Patient appears presenting prescriptions written in the names of other people [dea] 
(Cronbach’s α = .937) 
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The relevance placed upon the DEA factors was not significantly different when 
comparing the controlled medication against the non-controlled medication.  Again, as in the 
confirmatory factors, the means of both groups trended toward the “very relevant” side of the 7 
point scale (non-controlled mean=5.90, SD=1.13; controlled mean=5.94, SD=0.91).  
Determining the reasons the amoxicillin might have hovered close to the hydrocodone 
prescriptions in these factors might have to do with the widespread availability of the DEA 
resources to pharmacists.  These factors are perhaps widely recognized as information to look for 
as recommended by the DEA.  When determining the validity of a prescription, recognition of 
this information might trigger a questioning of validity of a prescription, without regard to the 
medication.  
Also, many of the items speak to the physical prescription itself.  Different color inks, 
different handwriting, potential photocopied prescription, etc. might give a pharmacist pause to 
question validity for any prescription regardless of the medication.    
Other  
Non-hypothesized data  
Significant differences found between groups. 
The patient is elderly 
The patient looks frail 
The patient is dressed in jeans and a t-shirt 
The patient is dressed in business attire 
The patient is female 
The patient is male 
The patient looks unkempt (messy hair, dirty clothes, etc.) 
The prescriber is from a different state than the patient. 
The prescriber is a pain specialist. 
The dose is at the upper limit of clinical guidelines for this medication. 
The quantity of medication prescribed seems higher than other prescriptions of this type. 
The patient has no prescription insurance 
The patient has visible bruises 
(Cronbach’s α = .905) 
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 In addition to the available information presented in published guides and other available 
resources, the pharmacists in the study were presented with other information that might be 
potentially available at the time of filling.  These pieces of information speak mainly to 
demographics (elderly, dressed, gender) and also to pain-management specific patients (pain 
specialist, upper guidelines).  The results were surprising.  The mean for each group were to the 
lower side of the 7 point scale used for attributing relevance to the information in deciding the 
validity of the prescription (non-controlled, 2.57 SD=0.99; controlled, 3.44 SD=0.89), but did 
register on the scale as higher than completely “not relevant.”  The scores were significantly 
different when compared to each other, meaning the controlled medication group gave higher 
relevance scores for the information provided.   
 The idea that demographics might play any part in helping a pharmacist determine the 
validity of a prescription is disturbing at first thought.  There is a potential for a person holding a 
valid pain medication prescription to have the prescription undergo a different level of relevance 
when the pharmacist is deciding the validity of the prescription.  Even if the relevance of the 
information was due to confirmatory reasons, as in “this patient type is not an issue for 
forgeries,” the competing idea that a group of people might get a prescription deemed invalid due 
to a relevance of demographics is disturbing.  Hopefully, demographics are not the only 
information that a pharmacist uses to make a decision on validity and that collective information 
about the patient and the prescription itself will ultimately determine a pharmacists judgment of 
its validity. 
Again, in these scenarios the means for each group were significant when compared to 
each other, indicating there was more relevance placed on the controlled medication scenario, 
but both scores did fall on the lower end of the 7 point scale.  Further research would be needed 
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to determine to what extent demographic information might actually contribute to a pharmacist 
determining the validity of a prescription.  
Pharmacists have to process a lot of information.  This study indicates that the medication 
will influence the information (or factors) that pharmacists deem to be relevant when considering 
the validity of prescriptions.  This study asked pharmacists to consider each piece of information 
independently.  More work is needed to fully understand whether these pieces of information are 
considered alone and how the information and its relevance ultimately influences pharmacists’ 




This study compared an antibiotic to a schedule III controlled substance.  In an attempt to 
begin to understand whether the controlled status influences the relevance that pharmacists place 
on specific pieces of information or if it is driven by the likelihood of a medication to be sought 
illegally by patients, carisoprodol, a muscle relaxant, was included in the study as a secondary 
analysis.  This drug has abuse potential and was not a scheduled controlled medication in all but 
eighteen states (http://www.deadiversion.usdoj.gov/drugs_concern/carisoprodol.htm).  Because 
of its mainly non-scheduled non-controlled status and its abuse potential, this drug was chosen to 
also be tested along with the non-controlled amoxicillin and the controlled hydrocodone.  This 
drug was chosen originally to test a medication with abuse potential (carisoprodol) versus a drug 
that had a scheduled controlled status and abuse potential (hydrocodone) to study if pharmacists 
regarded a higher level of relevance with a scheduled versus a non-scheduled medication.  
In most states, at the start of this study, carisoprodol was non-controlled but recognized for its 
abuse potential by many state pharmacy boards (Reeves & Burke 2008).).  Shortly before the 
release of this study, the Deputy Administrator of the DEA issued a proposed rule “to place the 
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substance carisoprodol, including its salts, isomers, and salts of isomers whenever the existence 
of such salts, isomers, and salts of isomers is possible, into schedule IV of the Controlled 
Substances Act (CSA)” (http://www.deadiversion.usdoj.gov/fed_regs/rules/2009/fr1117.htm).  
Upon analysis it was found that the medications carisoprodol and hydrocodone had very 
similar profiles with regards to the relevance of the information available to a pharmacist at the 
time of filling.  The carisoprodol group and the hydrocodone/apap group were compared in pair 
wise fashion to determine if the differences in response means represented significant 
differences.  No significant differences (Hotelling’s Trace = .133, F = 1.172) were found 
between the two groups.  No significant mean differences, at the .05 level, were found for any of 
the factor means between the carisoprodol and hydrocodone/apap groups. (Table 10) 
 
Table 9: Mean response differences between the carisoprodol and hydrocodone/apap 












The amoxicillin group and carisoprodol comparison had a very similar profile to the 
amoxicillin and hydrocodone/apap group.  There were significant differences in the same factors 
for both sets of analysis. (Table 11) 




(at .05 level) 
Irrelevant Factor Mean .089 .791 







DEA Factor Mean .048 .847 
Other Factor Mean .208 .428 
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Table 10: Mean response differences between the carisoprodol and hydrocodone/apap 










*Difference significant at the .05 level 
 
 While not formally predicted or tested, these findings indicate that the relevance of 
information considered by pharmacists when determining the validity of prescriptions is likely to 
be influenced by the nature of the medication; specifically, the drug abuse likelihood or potential 




 This study has a number of limitations that warrant careful interpretation of the findings.  
The sample size obtained for analysis is relatively small and did not allow for a confirmatory 
factor analysis.  The minimum number of observations required for conducting a confirmatory 
factor analysis would be five times as many observations as the number of variables to have 
analyzed.  In this study with forty-two variables the actual achieved was far fewer than the 
minimum required factor analysis (Hair et al., 2005). 
Also, the study lacks generalizability.  There was an overwhelming homogeneity of the groups 
with too many independent pharmacists in the sample to achieve a good cross representation of 




(at .05 level) 
Irrelevant Factor Mean 1.176 * .000 






.885 * .002 
DEA Factor Mean .406 .110 
Other Factor Mean 1.075 * .000 
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all pharmacists.  Finally, scenario-based surveys may not mimic accurately a real situation for a 
pharmacist. 
 
The reliability coefficient, which measures the consistency of a scale, was poor for some of the 
factor groups.  There was poor reliability in some of the factor groups.  The irrelevant factors 
had a Cronbach’s α of .574 and the determinative factors had a Cronbach’s Alpha of .558.  





 Pharmacists have access to various pieces of information at the time of filling 
prescriptions.  As they determine the validity of the prescriptions that they fill, different pieces of 
information will be judged to be relevant.  The findings from this study indicate that the 
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 When filling prescriptions, there are many pieces of information available about patients and 
about the prescriptions. Sometimes information is not available. When it is available, it can 
sometimes be used to help determine the validity of a given prescription.  
 
Please assume that a patient, whom you have never seen before, presents a prescription for 
Amoxil® (amoxicillin) 500mg . Please rate each of the following items on its value to you in 
deciding if the prescription is valid for dispensing.  
 
In doing so, please a) assume that the following pieces of information are available for the 
Amoxil® prescription, b) consider each piece of information independently of one another, and 
c) indicate how relevant you believe each piece of information to be in determining the validity 





When filling prescriptions, there are many pieces of information available about patients and 
about the prescriptions. Sometimes information is not available. When it is available, it can 
sometimes be used to help determine the validity of a given prescription.  
 
Please assume that a patient, whom you have never seen before, presents a prescription for 
Soma® (carisoprodol) 350mg . Please rate each of the following items on its value to you in 
deciding if the prescription is valid for dispensing.  
 
In doing so, please a) assume that the following pieces of information are available for the 
Soma® prescription, b) consider each piece of information independently of one another, and c) 
indicate how relevant you believe each piece of information to be in determining the validity of 





When filling prescriptions, there are many pieces of information available about patients and 
about the prescriptions. Sometimes information is not available. When it is available, it can 
sometimes be used to help determine the validity of a given prescription.  
 
Please assume that a patient, whom you have never seen before, presents a prescription for 
Lortab® (hydrocodone/acetaminophen) 5/500mg . Please rate each of the following items on its 
value to you in deciding if the prescription is valid for dispensing.  
 
In doing so, please a) assume that the following pieces of information are available for the 
Lortab® prescription, b) consider each piece of information independently of one another, and c) 
 65
indicate how relevant you believe each piece of information to be in determining the validity of 






1 = Not relevant 2  3   4 5 6 7 = Very relevant  
 
 
1.    The patient is aggressive in demanding the prescription immediately [irr] 
2.    The dose of the prescription seems high [irr] 
3.    Patient lost the medication and this is a replacement [sus] 
4.    This medication accompanies another medication and the patient doesn’t 
want the other filled [sus] 
5.    From the profile, you see that the patient has had this medication before 
from another prescriber [sus] 
6.    The patient refuses to let you call the doctor to verify the prescription [conf] 
7.    The patient refuses a partial fill while you verify the prescription [conf] 
8.    The patient refuses to show you identification [conf] 
9.    There is a note in the profile that this patient has presented a forged 
prescription before [det] 
10.  The patient is elderly [att] 
11.  The patient looks frail [att] 
12.  The patient is dressed in jeans and a t-shirt [att] 
13.  The patient is dressed in business attire [att] 
14.  The patient is female [att] 
15.  The patient is male [att] 
16.  The patient looks unkempt (messy hair, dirty clothes, etc.) [att] 
17.  The prescriber is from a different state than the patient. [p att] 
18.  The prescriber is a pain specialist. [p att] 
19.  The prescriber has very clear and legible handwriting. [dea]  
20.  The dose is at the upper limit of clinical guidelines for this medication.  [th 
att] 
21.  The quantity of medication prescribed seems higher than other prescriptions 
of this type.[th att] 
22.  The prescription was written for an off label use [irr] 
23.  The patient uses “street drug” terminology to describe another medication he 
is taking [det] 
24.  The patient refuses generic substitution [sus] 
25.  The patient ask that the prescription not be run on their prescription drug 
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insurance  
26.  The medication quantities differ from usual medical usage [dea] 
27.The directions for use differ from usual medical usage 
[dea] 
28. The medication dosages differ from usual medical usage [dea] 
 
29.  The sig codes do not match acceptable standard abbreviations [dea] 
30.  The prescription appears to be photocopied 
[dea] 
31. The prescription directions are written in full with no abbreviations [dea] 
32. The prescription is written in different-color inks [dea] 
33. The prescription is written in different handwriting [dea] 
34. There are apparent erasure marks on the prescription [dea] 
35. A number of people appear simultaneously, or within a short time, all 
bearing similar prescriptions from the same physician [dea] 
36. Numerous "strangers," people, who are not regular patrons or residents of 
your community, suddenly show up with prescriptions from the same 
prescriber [dea] 
37. The prescription is written for significantly larger quantities compared to 
other practitioners in the area [dea] 
38. The patient appears to be returning too frequently [dea] 
39. The patient appears presenting prescriptions written in the names of other 
people [dea] 
40. The patient has no prescription insurance [att] 
41. The patient has visible bruises [att] 
42. The patient has a known history of opioid addiction [att] 
 
 
